Alternative polyadenylation determines the functional landscape of inverted Alu repeats.
MDM2
RNA localization
alternative polyadenylation
amyotrophic lateral sclerosis
antisense oligonucleotide
double-stranded RNA
inverted Alu repeats
p53 signaling pathway
post-transcriptional gene regulation
transposable element
Journal
Molecular cell
ISSN: 1097-4164
Titre abrégé: Mol Cell
Pays: United States
ID NLM: 9802571
Informations de publication
Date de publication:
30 Jan 2024
30 Jan 2024
Historique:
received:
14
06
2023
revised:
27
11
2023
accepted:
09
01
2024
medline:
4
2
2024
pubmed:
4
2
2024
entrez:
3
2
2024
Statut:
aheadofprint
Résumé
Inverted Alu repeats (IRAlus) are abundantly found in the transcriptome, especially in introns and 3' untranslated regions (UTRs). Yet, the biological significance of IRAlus embedded in 3' UTRs remains largely unknown. Here, we find that 3' UTR IRAlus silences genes involved in essential signaling pathways. We utilize J2 antibody to directly capture and map the double-stranded RNA structure of 3' UTR IRAlus in the transcriptome. Bioinformatic analysis reveals alternative polyadenylation as a major axis of IRAlus-mediated gene regulation. Notably, the expression of mouse double minute 2 (MDM2), an inhibitor of p53, is upregulated by the exclusion of IRAlus during UTR shortening, which is exploited to silence p53 during tumorigenesis. Moreover, the transcriptome-wide UTR lengthening in neural progenitor cells results in the global downregulation of genes associated with neurodegenerative diseases, including amyotrophic lateral sclerosis, via IRAlus inclusion. Our study establishes the functional landscape of 3' UTR IRAlus and its role in human pathophysiology.
Identifiants
pubmed: 38309276
pii: S1097-2765(24)00009-1
doi: 10.1016/j.molcel.2024.01.008
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests There is currently a pending patent filing for the ASOs used in this study for which J.K., K.L., and Y.K. are listed as inventors.